LY3434172
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Cancer
Conditions
Advanced Cancer
Trial Timeline
May 24, 2019 → Apr 29, 2021
NCT ID
NCT03936959About LY3434172
LY3434172 is a phase 1 stage product being developed by Eli Lilly for Advanced Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT03936959. Target conditions include Advanced Cancer.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Cancer were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03936959 | Phase 1 | Terminated |
Competing Products
20 competing products in Advanced Cancer